The FDA granted researchers a “breakthrough therapy designation” so they can study mushrooms.
For Daniel Marin Medina, an app widely associated with quick sex has become a source of limitless muses.
The VA won't help recruit veterans for an FDA-approved trial.
Dennis McKenna was already deep into psychedelics when he first tried ayahuasca in 1981. Him and his brother Terence had traveled to the Colombian Amazon ten years prior in search of oo-koo-he, psychedelic beans that come from the Anadenanthera peregrine tree. Instead, they discovered a psilocybin-containing mushroom called Stropharia cubensis, launching their careers as luminaries in the psychedelic field.
For Humboldt’s second-generation cannabis farmers, legalization doesn’t just threaten their crop—it threatens their values.
Thousands of people from around the world travel to the Amazon every year to drink ayahuasca for mental health conditions. Yet, there’s limited empirical data backing the extraordinary stories about the therapeutic effects of this ancient medicine.
These products are a part of a larger movement in the country to think about every aspect of women’s reproductive and sexual health — from the orgasm to pregnancy — as connected.
Jose Belen claims that without medical cannabis he would likely be dead.
Psilocybin—the active ingredient in psychedelic mushrooms—has already shown promise in treating alcoholism and cigarette addiction.
When the VA neglected to find Bob Mulcahey housing, he set up at a homeless encampment in the abandoned mills of Paterson, New Jersey.
There’s still a host of unknowns about how new state and local rules written to implement the California law legalizing adult recreational use of cannabis might make it difficult for startups, particularly those dealing directly with the cannabis plant, to operate.